Endocrine Testing Market by Test Type, Technology, End User, and by Region - Global Forecast to 2022-2033

The endocrine testing market size is estimated to be USD 4,607.1 million in 2022 and is expected to witness a CAGR of 8.67% during the forecast period 2023-2033. Increase in health awareness and a rise in the prevalence of lifestyle diseases among adults, new technological developments to produce results rapidly and accurately are factors contributing to the market growth. However, lack of skilled IT workerforce and high deployment costs is expected to hinder the growth.

Increase in health awareness and a rise in the prevalence of lifestyle diseases among adults is expected to propel the market growth. This increase in knowledge has fueled the development of home healthcare and point-of-care (POC) equipment that produce results more quickly and effectively. The cost-effective home healthcare and POC devices are simple to use and aimed at the growing geriatric population and adults. The International Diabetes Federation estimates that 537 million people already have diabetes as of 2021, and that number will rise to 643 and 783 million by the years 2030 and 2045, respectively.

New technological developments to produce results rapidly and accurately is predicted to fuel the market growth during the forecast period. For instance, tandem mass spectrometry (MS/MS) or the coupling of mass spectroscopy with liquid chromatography (LC/MS) both produce results that are more precise and accurate. Additionally, organisations as Agilent Methods, Inc. are concentrating on creating brand-new alternative analysis technologies, such as the usage of LC-ICP-MS for more accurate thyroid hormone testing. Such technological advancements open up a large number of opportunities for market players, and they are anticipated to significantly accelerate the expansion of the endocrine testing market.

Segmentation

By Test type

The market is categorized into progesterone test, cortisol test, testosterone test, prolactin test, estradiol (E2) test, luteinizing hormone test, insulin test, follicle stimulating hormone test, thyroid stimulating hormone test, human chorionic gonadotrophin hormone test, others. In 2022, the human chorionic gonadotrophin hormone test segment accounted for the highest revenue share due to the demand for quantitative hCG estimation at hospitals or laboratories, along with the prevalence of simple self-test pregnancy kits. Additionally, this segment's revenue is being driven by the rising number of pregnant females and the measurement of hCG levels to detect anomalies at various stages of pregnancy. Furthermore, use of hCG in the treatment of infertility in both men and women will fuel the expansion of the endocrine testing industry. Additionally, TSH testing resulted in a sizable revenue. TSH is a crucial immune response regulator and is related to regulating the body's levels of several hormones, including progesterone and hCG. The market expansion for TSH testing is driven by the above functions of TSH and the occurrence of thyroid conditions including cancer. According to Cancer.Net, more than 43,500 persons will have a thyroid cancer diagnosis in the United States in 2022.

By Technology

The market is categorized into immunoassay, mass spectroscopy, nucleic acid based, and chromatography. In the global market, the immunoassay segment accounted for the largest revenue share in 2022 owing to availability of numerous devices and analyzers that use various immunoassay technologies for detection. The largest revenue generation of the segment is also attributed to the presence of immunoassay-based tests panels for endocrine and reproductive function offered by many prominent players. Contrarily, new approaches to hormone testing have been created as a result of recent technological advancements. For endocrine testing panels, techniques including mass spectroscopy, chromatography, and nucleic acid-based detection technologies are taking over and offering precise results with a faster turnaround time. Additionally, combining techniques as mass spectrometry with liquid chromatography produces consistent results and gets around problems with conventional techniques including cross-reactivity.

By End User

The market is segmented into ambulatory care centres, hospitals, commercial laboratories, and others. In 2022, the commercial laboratories segment accounted for the largest revenue share owing to capability of at-home collection services and the accessibility of a variety of test panels. Commercial laboratories are additionally anticipated to experience the fastest increase in the upcoming years. This can be attributed to rising health knowledge among people and ongoing endocrine testing to track disease progression and manage hereditary risk factors. Additionally, the availability of reports by these commercial settings on digital platforms accelerates their growth trajectory. For instance, Laboratory Corporation of America Holdings, or LabCorp, a U.S.-based diagnostics company, established a digital portal in February 2022 that allowed online test ordering. In April 2022, the company then introduced a diagnostic test collecting service that was available at homes.

Regional Markets

In 2022, North America region accounted for the highest revenue in the endocrine testing market and is expected to maintain its dominance during the forecast period. This is attributed to the high prevalence of diabetes and obesity, existence of reimbursement bodies, availability of affordable and accessible alternatives, government funding programmes for improving healthcare settings, and the proliferation of diagnostic companies. For instance, since the start of its financing programme, the American Thyroid Association, a group dedicated to funding research for the treatment of thyroid disorders, has funded nearly USD 2.8 million over 105 grants. Additionally, the competition in the market for endocrine testing is fuelled by the presence of major firms in this area, which leads to a variety of product offers. The demand for routine endocrine testing in the Asia Pacific region has increased over the past few decades due to factors such as expanding medical and diagnostics sector, improved healthcare systems, the occurrence of disease among the older population, and rising personal healthcare spending. In addition, the APAC region is experiencing a rise in research activity aimed at improving disease detection & treatment. All of this will generate a sizeable increase, with Asia Pacific showing the fastest CAGR.

Competitor Insights

Some of the key players operating in the endocrine testing market are bioMerieux SA, AB Sciex, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Agilent Technologies Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Abbott Laboratories, Laboratory Corporation of America Holdings, and Ortho Clinical Diagnostics.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

For instance, DiaSorin S.p.A. declared that it has launched the LIAISON Testosterone xt test with CE marking in August 2020. This test will work with the company's LIAISON XL instrument for the development of endocrine assays to identify both hypogonadism and hyperandrogenism.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including test type, technology, and end user from 2023 to 2033.

Segmentation: Endocrine Testing Market Report 2022 - 2033

Test Type (Revenue, USD Million), 2022 - 2033

• Progesterone Test
• Cortisol Test
• Testosterone Test
• Prolactin Test
• Estradiol (E2) Test
• Luteinizing Hormone Test
• Insulin Test
• Follicle Stimulating Hormone Test
• Thyroid Stimulating Hormone Test
• Human Chorionic Gonadotrophin Hormone Test
• Others

Technology (Revenue, USD Million), 2022 - 2033

• Immunoassay
• Mass Spectroscopy
• Nucleic Acid Based
• Chromatography

End user (Revenue, USD Million), 2022 - 2033

• Ambulatory Care Centres
• Hospitals
• Commercial Laboratories
• Others

By Region (Revenue, USD Million), 2022 - 2033

North America

• U.S.
• Canada

Europe

• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East & Africa

• South Africa
• GCC
• Rest of MEA